Medicine and Dentistry
Acute Myeloid Leukemia
89%
Multiple Myeloma
61%
Overall Survival
54%
Haemophilia A
53%
Hematopoietic Cell
50%
Diseases
46%
COVID-19
45%
Neoplasm
45%
Transplantation
40%
Bleeding
39%
Von Willebrand Factor
39%
Von Willebrand Disease
36%
Cell Transplantation
34%
Minimal Residual Disease
33%
Hazard Ratio
32%
Progression Free Survival
32%
Arm
32%
Diagnosis
27%
Randomized Controlled Trial
27%
Diffuse Large B-Cell Lymphoma
27%
Systematic Review
26%
Acute Leukemia
26%
Quality of Life
25%
Hodgkin's Lymphoma
24%
Thrombosis
23%
Clinical Trial
23%
Malignant Neoplasm
21%
Cancer
21%
Myelodysplastic Syndrome
21%
Myeloma
20%
Meta-Analysis
20%
Adverse Event
19%
Leukemia
19%
Blood Stasis
18%
Pulmonary Embolism
18%
Cohort Analysis
17%
Autologous Stem Cell Transplantation
17%
Acute Lymphoblastic Leukemia
17%
Cyclophosphamide
17%
Dexamethasone
17%
Large-Cell Lymphoma
17%
Bleeding Disorder
17%
Infection
17%
Blood Clotting Factor 8
16%
Lenalidomide
15%
Allogeneic Hematopoietic Stem Cell Transplantation
15%
Platelet
15%
Surgery
15%
Allogeneic Stem Cell Transplantation
14%
Hematologic Malignancy
14%
Hematology
14%
B-Cell Chronic Lymphocytic Leukemia
13%
Radiation Therapy
13%
Biological Marker
13%
Desmopressin
13%
Hematopoiesis
12%
Hemostat
12%
Breast Cancer
12%
Polyethylene Terephthalate
12%
Rituximab
11%
Graft Versus Host Reaction
11%
Rectum Cancer
11%
Severe Acute Respiratory Syndrome Coronavirus 2
11%
Patient with Hemophilia
11%
COVID-19 Vaccination
11%
Positron Emission Tomography-Computed Tomography
11%
Conditioning
11%
Odds Ratio
11%
Endothelial Cell
10%
Haemophilia B
10%
Gene Therapy
10%
Chimeric Antigen Receptor T-Cell
10%
Fluorodeoxyglucose F 18
10%
Fibrinolysis
10%
Survival Rate
10%
Health Care Cost
9%
Patient-Reported Outcome
9%
Acute Myelogenous Leukemia
9%
Precursor
9%
B Cell
9%
Positron Emission Tomography
9%
Pharmacokinetics
9%
D-Dimer
9%
Vitamin K Antagonist
9%
Retrospective Study
9%
Cumulative Incidence
9%
Venous Thromboembolism
9%
Immunity
9%
Radiomics
8%
Organoid
8%
Chemoradiotherapy
8%
Chimeric Antigen Receptor T-Cell Immunotherapy
8%
Population
8%
Bortezomib
8%
Liver Transplantation
8%
Acute Pulmonary Embolism
8%
Venetoclax
8%
Stem Cell Transplant
8%
Induction Chemotherapy
8%
Immunoglobulin Producing Cell
8%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
58%
Multiple Myeloma
55%
Diseases
53%
Haemophilia A
47%
Overall Survival
47%
Pharmacokinetics
42%
Chemotherapy
34%
Progression Free Survival
34%
Neoplasm
30%
Bleeding
30%
Dexamethasone
28%
Von Willebrand Factor
27%
Randomized Controlled Trial
24%
Adverse Event
24%
Clinical Trial
24%
Von Willebrand Disease
23%
Remission
22%
Myelodysplastic Syndrome
21%
Minimal Residual Disease
21%
Diffuse Large B Cell Lymphoma
20%
Malignant Neoplasm
18%
Cyclophosphamide
18%
Blood Clotting Factor 8
18%
Lenalidomide
16%
Cohort Study
15%
Pomalidomide
15%
Thrombosis
15%
Coronavirinae
15%
Chronic Lymphatic Leukemia
15%
Daratumumab
14%
Anemia
14%
Rituximab
14%
Infection
13%
Large Cell Lymphoma
13%
Chimeric Antigen Receptor
13%
Haemophilia B
12%
Acute Leukemia
11%
Leukemia
11%
Hodgkin Disease
11%
Biological Marker
11%
Myeloma
11%
Bortezomib
10%
Blood Stasis
10%
Breast Cancer
10%
Lung Embolism
9%
Acute Lymphoblastic Leukemia
9%
Polyethylene Terephthalate
9%
Cytarabine
9%
Desmopressin
8%
Blood Clotting Factor 9
8%
Fibrinogen
8%
Anticoagulant Agent
8%
Venous Thromboembolism
8%
SARS Coronavirus
8%
Blood Clotting Factor 8 Concentrate
7%
Cytokine Release Syndrome
7%
Thrombin
7%
Survival Rate
7%
Graft Versus Host Reaction
6%
Monotherapy
6%
Cerebrovascular Accident
6%
Bleeding Disorder
6%
Event Free Survival
6%
Frailty
6%
Antivitamin K
6%
Atrial Fibrillation
6%
Fibrinolytic Agent
6%
Side Effect
6%
Chronic Disease
6%
Hematologic Malignancy
6%
Placebo
6%
Fludarabine
6%
Rheumatoid Arthritis
6%
Cisplatin
6%
Inflammatory Arthritis
6%
Doxorubicin
6%
Nonhodgkin Lymphoma
5%
Paclitaxel
5%
Non Small Cell Lung Cancer
5%
Alteplase
5%
Immunocompromised Patient
5%
Hyperimmune Globulin
5%
Venetoclax
5%
Immunotherapy
5%
Comorbidity
5%
Cytokine
5%
Congestive Heart Failure
5%
Brain Ischemia
5%
Flow Cytometry
5%
Disease Exacerbation
5%
Thrombocytopenia
5%
D Dimer
5%
Immunology and Microbiology
Myeloid
100%
Hematopoietic Cell
66%
Multiple Myeloma
66%
Overall Survival
49%
B Cell
38%
Cell Transplantation
35%
Cyclophosphamide
29%
Progression Free Survival
29%
Dexamethasone
24%
Daratumumab
19%
Blood Plasma
17%
COVID-19
17%
Allogeneic Stem Cell Transplantation
16%
T Cell
16%
Conditioning
16%
Graft-Versus-Host Disease
16%
Immunity
15%
Arm
15%
Lenalidomide
15%
Hematopoiesis
14%
Allogeneic Hematopoietic Stem Cell Transplantation
13%
Rituximab
11%
Pomalidomide
11%
Weibel Palade Body
11%
Allele
10%
Precursor
10%
Cord Blood Stem Cell Transplantation
10%
Secretion (Process)
9%
Immunoglobulin Producing Cell
9%
Drug Megadose
9%
Stem Cell
9%
Factor VIII
9%
Fibrinolysis
8%
Mesenchymal Stem Cell
8%
Transcriptomics
8%
Survival Rate
8%
Tyrosine
8%
Next Generation Sequencing
8%
Neutrophil
8%
Autologous Stem Cell Transplantation
8%
Stem Cell Transplant
8%
Platelet
7%
Chimeric Antigen Receptor T-Cell
7%
Lineages
7%
Recurrence Free Survival
7%
Epstein Barr Virus
7%
Lymph Node
7%
Positron Emission Tomography
7%
Macrophage
7%
Severe Acute Respiratory Syndrome Coronavirus 2
7%
Cytokine
7%
Metabolic Tumor Volume
6%
Thrombin
6%
Chronic Graft Versus Host Disease
6%
CD38
6%
Hematopoietic Stem Cell Transplantation
6%
Cell Maturation
6%
Immune Response
6%
Umbilical Cord Blood
6%
Antibody Titer
6%
Gene Mutation
6%
Acute Graft Versus Host Disease
6%
Natural Killer Cell
6%
Hemostasis
6%
Gene Expression
5%
RNA Sequence
5%
Liver Transplantation
5%
Positron Emission Tomography-Computed Tomography
5%
Central Nervous System
5%
Methotrexate
5%
Zebra Fish
5%
Colony Forming Cell
5%
Allograft
5%
Gene Expression Assay
5%
Enhancer Region
5%
Immunocompetent Cell
5%
Mouse Model
5%
Innate Lymphoid Cell
5%